OLEMA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company's 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Cynthia Butitta

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Cynthia Butitta”): 44,675,129 for, 11,733,848 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the three nominees for Class II director to hold office until the Company's 2028 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 8,504,933 for, 1,258,844 withheld, 28,750 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company's 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Cyrus Harmon, Ph.D.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Cyrus Harmon, Ph.D.”): 43,838,514 for, 12,570,463 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the three nominees for Class II director to hold office until the Company's 2028 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 8,466,368 for, 1,297,409 withheld, 28,750 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company's 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Graham Walmsley, M.D., Ph.D.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Graham Walmsley, M.D., Ph.D.”): 44,120,432 for, 12,288,545 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the three nominees for Class II director to hold office until the Company's 2028 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 8,465,536 for, 1,298,241 withheld, 28,750 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation Final Voting Results”): 54,057,177 for, 2,297,482 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of OLEMA PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “14A Executive Compensation Approval, on an advisory basis, of the compensation of the Company's named executive officers.” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Advisory vote to approve named executive compensation” (2 managers, 6,696,640 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 44 managers: 8,700,566 for, 832,811 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 119 managers: 38,271,903 for, 377,631 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 62,732,079 for, 24,064 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 9,729,395 for.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.